Ovid Therapeutics Stock Price, Forecast & Analysis (NASDAQ:OVID)

Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."

Ovid Therapeutics Inc (NASDAQ:OVID) released its quarterly earnings results on Friday, November, 8th. The company reported ($0.43) EPS for the quarter, topping the Zacks' consensus estimate of ($0.45) by $0.02. View Ovid Therapeutics' Earnings History.

Ovid Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Ovid Therapeutics.

7 Wall Street analysts have issued 1-year target prices for Ovid Therapeutics' stock. Their forecasts range from $10.00 to $27.00. On average, they anticipate Ovid Therapeutics' stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 451.2% from the stock's current price. View Analyst Price Targets for Ovid Therapeutics.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ovid Therapeutics.

Press coverage about OVID stock has been trending somewhat negative on Thursday, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Ovid Therapeutics earned a daily sentiment score of -1.4 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Ovid Therapeutics.

Ovid Therapeutics saw a drop in short interest during the month of October. As of October 31st, there was short interest totalling 424,100 shares, a drop of 35.6% from the September 30th total of 659,000 shares. Based on an average daily volume of 610,800 shares, the days-to-cover ratio is presently 0.7 days. Approximately 1.8% of the shares of the stock are short sold. View Ovid Therapeutics' Current Options Chain.

Some companies that are related to Ovid Therapeutics include Provention Bio (PRVB), Recro Pharma (REPH), MacroGenics (MGNX), Rigel Pharmaceuticals (RIGL), CymaBay Therapeutics (CBAY), Innate Pharma (IPHYF), AC Immune (ACIU), Ardelyx (ARDX), Assembly Biosciences (ASMB), Lexicon Pharmaceuticals (LXRX), Merus (MRUS), Lannett (LCI), Dynavax Technologies (DVAX), Arcus Biosciences (RCUS) and BioSpecifics Technologies (BSTC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ovid Therapeutics investors own include Corbus Pharmaceuticals (CRBP), Zynerba Pharmaceuticals (ZYNE), Anavex Life Sciences (AVXL), Amicus Therapeutics (FOLD), Heron Therapeutics (HRTX), Marinus Pharmaceuticals (MRNS), Progenics Pharmaceuticals (PGNX), Sorrento Therapeutics (SRNE), Verastem (VSTM) and AcelRx Pharmaceuticals (ACRX).

(OVID) raised $80 million in an initial public offering (IPO) on Friday, May 5th 2017. The company issued 5,000,000 shares at $15.00-$17.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

Ovid Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Granite Point Capital Management L.P. (0.90%) and Commonwealth Equity Services LLC (0.04%). Company insiders that own Ovid Therapeutics stock include Douglas E Williams, Jeremy M Levin and Karen Bernstein. View Institutional Ownership Trends for Ovid Therapeutics.

OVID stock was sold by a variety of institutional investors in the last quarter, including Granite Point Capital Management L.P.. View Insider Buying and Selling for Ovid Therapeutics.

OVID stock was purchased by a variety of institutional investors in the last quarter, including Commonwealth Equity Services LLC. Company insiders that have bought Ovid Therapeutics stock in the last two years include Douglas E Williams, Jeremy M Levin and Karen Bernstein. View Insider Buying and Selling for Ovid Therapeutics.

Shares of OVID can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OVID stock can currently be purchased for approximately $2.54.

Ovid Therapeutics has a market capitalization of $121.45 million. The company earns $-51,980,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Ovid Therapeutics employs 55 workers across the globe.View Additional Information About Ovid Therapeutics.

The official website for Ovid Therapeutics is http://www.ovidrx.com/.

Ovid Therapeutics' mailing address is 1460 BROADWAY SUITE 15044, NEW YORK NY, 10036. The company can be reached via phone at 646-661-7661 or via email at [email protected]